Indeed, overcoming the SAMHD1‐mediated barrier to ara‐C efficacy that is responsible for worse OS in AML (Herold et al, 2017b; Rassidakis et al, 2018) is particularly relevant for developing countries as they carry the major disease burden and death toll of AML (Ferlay et al, 2015). This evidence concerns the gene SAMHD1 and acute myeloid leukemia.